Is Selling Teligent, Inc. (TLGT) Here a Winning Strategy?

March 14, 2018 - By Dolores Ford

The stock of Teligent, Inc. (NASDAQ:TLGT) hit a new 52-week low and has $2.45 target or 5.00 % below today’s $2.58 share price. The 5 months bearish chart indicates high risk for the $137.77M company. The 1-year low was reported on Mar, 14 by If the $2.45 price target is reached, the company will be worth $6.89M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock increased 0.39% or $0.01 during the last trading session, reaching $2.58. About 385,674 shares traded. Teligent, Inc. (NASDAQ:TLGT) has risen 64.58% since March 14, 2017 and is uptrending. It has outperformed by 47.88% the S&P500.

More news for Teligent, Inc. (NASDAQ:TLGT) were recently published by:, which released: “Teligent, Inc. to Present at the Raymond James 39th Annual Institutional …” on March 05, 2018.‘s article titled: “Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Lotion USP …” and published on February 14, 2018 is yet another important article.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, makes, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company has market cap of $137.77 million. The firm sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It currently has negative earnings. It also develops, makes, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: